Trial
NCT00005047
4B951, Combination Chemotherapy in Treating Patients With Bladder Cancer
Phase IIITERMINATEDEFFICACY/FUTILITYConfidence: HIGH
Sponsor
SWOG Cancer Research Network
Collaborators
National Cancer Institute (NCI); NCIC Clinical Trials Group; University of Southern California
Condition
Bladder Cancer
Intervention
cisplatin
Why stopped
Accrual was halted on the basis of the Data and Safety Monitoring Board review of a futility analysis.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2017-06-08